, MD Division of Hepatobiliary and ram That John Cameron Built ’ ’ Pancreatic Surgery ‘ ‘ The Prog

&NA; The pancreatic surgery program at Johns Hopkins is recognized as being among the top programs in the field. It is part of the newly formed John L. Cameron Division of HPB surgery. This division of surgery is a highly productive group of academic surgeons in terms of clinical volume, research endeavors, and education. The division functions as part of a large multidisciplinary group at Johns Hopkins. The program has an interesting history and can trace its roots back to the actions of a single individual—John L. Cameron. The John L. Cameron Division of HPB surgery and the Johns Hopkins Pancreas Disease program would not exist without him. It is the program that Dr Cameron built.

[1]  J. Cameron,et al.  Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma , 2017, Annals of surgery.

[2]  M. Makary,et al.  Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers , 2017, Proceedings of the National Academy of Sciences.

[3]  K. Lillemoe.  Surgical Mentorship: A Great Tradition, But Can We Do Better for the Next Generation? , 2017, Annals of surgery.

[4]  J. Cameron,et al.  Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas , 2017, Annals of surgery.

[5]  P. Lipsett,et al.  Assessing the Magnitude of a Surgical Career Through His Trainees: The John L. Cameron Legacy Factor. , 2017, Annals of surgery.

[6]  M. Pittman,et al.  Genetic Syndromes with Pancreatic Manifestations. , 2016, Surgical pathology clinics.

[7]  L. Wood,et al.  Genetics of pancreatic neuroendocrine tumors: implications for the clinic , 2015, Expert review of gastroenterology & hepatology.

[8]  J. Cameron,et al.  Two thousand consecutive pancreaticoduodenectomies. , 2015, Journal of the American College of Surgeons.

[9]  E. Jaffee,et al.  PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors , 2015, Journal of immunotherapy.

[10]  R. Hruban,et al.  Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation , 2014, Cancer Immunology Research.